Positive and Negative Transcriptional Regulation of the Foxp3 Gene is Mediated by Access and Binding of the Smad3 Protein to Enhancer I  by Xu, Lili et al.
Immunity
ArticlePositive and Negative Transcriptional Regulation
of the Foxp3 Gene is Mediated by Access
and Binding of the Smad3 Protein to Enhancer I
Lili Xu,1 Atsushi Kitani,1 Christina Stuelten,2 George McGrady,3 Ivan Fuss,1 and Warren Strober1,*
1Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases
2Cell and Cancer Biology Branch, National Cancer Institute
3Oral Infection and Immunity Branch, National Institute of Dental and Craniofacial Research
National Institutes of Health, Bethesda, MD 20892, USA
*Correspondence: wstrober@niaid.nih.gov
DOI 10.1016/j.immuni.2010.09.001SUMMARY
The molecular mechanisms underlying retinoic acid
(RA) augmentation of T cell receptor (TCR) and trans-
forming growth factor-b (TGF-b)-induced Foxp3 tran-
scription and inhibition of the latter by cytokines such
as IL-27 were here shown to be related processes
involving modifications of baseline (TGF-b-induced)
phosphorylated Smad3 (pSmad3) binding to a con-
served enhancer region (enhancer I). RA augmenta-
tion involved the binding of retinoic acid receptor
(RAR) and retinoid X receptor (RXR) to a dominant
site in enhancer I and a subordinate site in the
promoter. This led to increased histone acetylation
in the region of the Smad3 binding site and increased
binding of pSmad3. Cytokine (IL-27) inhibition
involved binding of pStat3 to a gene silencer in
a second conserved enhancer region (enhancer II)
downstream from enhancer I; this led to loss of
pSmad3 binding to enhancer I. Thus, control of acces-
sibility and binding of pSmad3 provides a common
framework for positive and negative regulation of
TGF-b-induced Foxp3 transcription.
INTRODUCTION
It is now well established that CD4+ regulatory T cells (Tregs) can
be recruited from unselected CD4+ nonregulatory T cells in the
peripheral (extra-thymic) lymphoid compartment; the regulatory
activity of these cells augment the regulatory activity of thymus-
derived Tregs, particularly at inflammatory sites. The major
driving force of such recruitment is transforming growth factor-
b (TGF-b), which has been shown to induce T cell receptor
(TCR)-stimulated CD25 nonregulatory T cells to express the
intracellular transcription factor that directs Treg function,
Foxp3 (Zheng et al., 2002). Recently, the molecular basis of
such induction was clarified, at least in part, by Tone et al.,
who showed that the Foxp3 gene was regulated by Smad3
and NFAT transcription factors that bind to sites in an enhancer
region (enhancer I) located in an intron between untranslatedImexon 2a and exon 1 upstream of the ATG start site of the
Foxp3 gene (Tone et al., 2008). Subsequently, Smad3 is
recruited to a promoter site where it forms part of a complex
enhanceosome also composed of c-Rel, p65, NFAT, and
CREB binding to a promoter site (Ruan et al., 2009). In addition,
Zheng et al. (2010) have recently reported that enhancer 1
activity is required for induced Treg development.
Several other factors have also been shown to modulate regu-
latory cell and Foxp3 induction in addition to TGF-b and TCR
stimulation. For example, all trans retinoic acid (RA) produced
by CD103+ dendritic cells in the gastrointestinal mucosa has
been shown to augment TGF-b and TCR inductive effects but
to have no inductive effects on its own (Coombes et al., 2007;
Mucida et al., 2007). The mechanism of RA enhancement is
controversial. One group of investigators maintain that the effect
is indirect in that RA actsmainly to inhibit the production of proin-
flammatory cytokines that would otherwise inhibit the induction
of Foxp3+ regulatory T cells (Hill et al., 2008). Other investigators
maintain that the RA effect is direct and is not simply reversing
the inhibitory activity of cytokines (Mucida et al., 2009). These
different views are best resolved with a molecular analysis of
RA effects, such as the analysis reported here.
Various cytokines also exert control on regulatory T cell and
Foxp3 induction, both in a negative and positive direction. IL-6
and IL-27, for instance, are strongly inhibitory of TCR and
TGF-b inductive effects, presumably through their shared
capacity to activate Stat3. Indeed, some evidence supporting
this idea has been presented, but the mechanism of inhibition
is still incompletely understood as Stat3 binding sites are lacking
in the Foxp3 promoter and the above mentioned enhancer I
region (Neufert et al., 2007; Huber et al., 2008). IL-2, alternatively,
exerts a positive effect on TCR and TGF-b induction, but again,
the mechanism is unclear because the Stat5 binding site so far
identified has no known relationship to previously identified
Foxp3 transcriptional control regions (Yao et al., 2007; Kim and
Leonard, 2007).
In the present study, we explored TCR-TGF-b-RA induction of
Foxp3 expression using a combined cellular and molecular
approach involving the use of cell lines transfected with a Foxp3
promoter and enhancer-driven luciferase constructs, as well as
ChIP analysis of transcription factor binding in CD4+T cells. A
key finding was that TCR-TGF-b induction of Foxp3 was exqui-
sitely dependent on the generation of phosphorylated Smad3munity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc. 313
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Regulation of Foxp3 via Control of Smad3 Binding(pSmad3) and that RA enhanced such induction by facilitating
increased binding of pSmad3 to the enhancer identified by Tone
et al. (2008). In addition, IL-27 inhibited such induction (as well
as induction by TGF-b and RA) by generating pSTAT3, which
then acted as an inhibitor by binding to a conserved enhancer
(enhancer II) downstream of enhancer I, and inhibited binding of
pSmad3 to enhancer I. Thus, factors that enhance and inhibit
Foxp3 expression are acting reciprocally to control the binding
of pSmad3 to enhancer I.
RESULTS
An AP-1 Site Located in Foxp3 Enhancer I Region Plays
an Important Role in TCR- and TGF-b-Induced Foxp3
Expression
On the basis of the fact that both TCR and TGF-b signals induce
the activation of c-Jun(activator protein-1)(AP-1) via the
mitogen-activated protein kinase (MAPK) pathway, we began
our investigation of the molecular mechanisms governing TCR-
TGF-b induction of Foxp3 with studies to determine if such
induction was c-Jun(AP-1) dependent.
In initial studies to address this question, we subjected CD4+
T cells from Foxp3-IRES-GFP gene targeted (Foxp3-GFP) mice
to anti-CD3-anti-CD28 (anti-TCR) plus TGF-b (TCR- TGF-b)
stimulation in the presence (or absence) of a c-Jun N-terminal
kinase (JNK) inhibitor, then, after 4 days, assayed the cells for
Foxp3 expression by flow cytometry. As shown in Figure 1A,
the presence of the inhibitor reduced the percentage of CD4+
T cells that express GFP (Foxp3) following stimulation from
49.9% to 12.1%. In a parallel study, we assessed Foxp3 expres-
sion in CD4+ T cells from conventional B6 mice after stimulation
by enumerating cells that stain with fluorescent anti-Foxp3 anti-
body. In this case, the addition of JNK inhibitor reduced the
percentage of Foxp3+ cells from 45.4% to 11%. In a parallel
study also shown in Figure S1 available online, we found that
p38 and extracellular signal-regulated kinase (ERK) inhibitors
had only marginal blocking effects on Foxp3 induction.
In additional studies, we determined the contribution of AP-1
to Foxp3 transcription in reporter assays conducted in mouse
lymphoma T cell line LBRM-33 4A2 (hereafter called LBRM cells)
or a EL-4 cell line, clone LAF (hereafter called EL-4 cells). As
shown in Figure 1B, the reporter construct consisted of firefly
luciferase reporter driven by a 1 kb Foxp3 promoter fragment
(944 to +75), linked in tandem to a previously identified
182 bp enhancer region (+2053 to +2235). This enhancer region
(here identified as enhancer I) has been shown to contain a func-
tional nuclear factor of activated T cells (NFAT) binding site and
a Smad binding site at +2130 to +2139 and +2144 to +2147,
respectively (Tone et al., 2008). The core sequence of an NFAT
site (GGAAA) is often positioned 3 base pairs downstream
from an AP-1 site, and during transcription, AP-1 forms
a complex with NFAT that modifies NFAT transcriptional activity.
Indeed, such an AP-1 site was present just upstream of the NFAT
site in the Foxp3 enhancer at +2122 to +2129 (TGAAGCC).
As shown in Figure 1C, we found that reporter activity was very
low in unstimulated transfected cells but was increased upon
TCR stimulation and further increased upon TCR-TGF-b stimula-
tion, indicating the positive effect of TGF-b signaling on Foxp3
transcription in the presence of TCR stimulation. In contrast,314 Immunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc.TCR-TGF-b stimulation of cells with a construct containing
a deletion of the above described AP-1 site induced little lucif-
erase activity. Similar results were obtained with a reporter
construct transfected into EL-4 cells. These data plus the flow-
cytometric data above (Figure 1A) clearly indicate that an AP-1
binding site adjacent to NFAT is an important factor in TGF-
b-mediated induction of Foxp3 transcription.
A search of the Foxp3 gene disclosed several additional AP-1
sites, including a site in the promoter region at 256 to 262
(TGACTTG) nearest to the transcription start site. To determine
whether this latter AP-1 site also played a role in Foxp3 transcrip-
tion,we compared the luciferase signals generated by TCR-TGF-
b-stimulated EL-4 and LBRM cells transfected with a Foxp3
promoter-enhancer 1-driven luciferase construct with a deletion
of the promoter AP-1 site with signal generated in cells trans-
fected with the same construct without the deletion. As also
shown in Figure 1C, the luciferase signals generated by the
construct bearing the promoter AP-1 site deletion was not
substantially reduced compared to the signals generated by
the intact construct. Thus, the AP-1 site located in the promoter
region nearest to the transcriptional start site appears to play
no substantial role in Foxp3 transcription; however, it remains
possible that other AP-1 sites in the promoter have amore impor-
tant role or that AP-1 sites in the promoter act collectively to influ-
ence Foxp3 transcription.
In further studies we considered the possibility that the
control of Foxp3 transcription exerted by AP-1 (or, more
correctly, the NFAT-AP-1 complex) was not because of the
direct effect of this complex acting as a Foxp3 transcription
factor, but rather, it was due to an indirect effect involving the
ability of NFAT-AP-1 to regulate the binding of pSmad3 to an
adjacent enhancer I site. To explore this possibility, we deter-
mined pSmad3 binding to the enhancer I site by ChIP assays
of primary CD4+ T cells in the presence and absence of a JNK
inhibitor. These studies are discussed below in a different and
more appropriate context.
TGF-bRI Kinase Activity Is Essential for TCR-TGF-b-
Induced Foxp3 Expression in Murine T Cells
TGF-b signaling through the heterodimeric TGF-bRI-RII results in
activation of the MAPK pathway as well as the Smad pathway
(Derynck and Zhang, 2003). These pathways are activated inde-
pendently: the MAP kinase pathway via E3 activity of TNF
receptor associated factor 6 (TRAF6) and the activation of
TGF-b-activated kinase 1 (TAK1) in a TGF-bRI receptor kinase-
independent manner and the Smad pathway via TGF-bRI kinase
activity (Sorrentino et al., 2008). To determine whether the contri-
bution of TGF-b stimulation to Foxp3 expression depends on the
receptor kinase activity, we assessed TGF-b induction of Foxp3
in cells exposed to the TGF-bR1 kinase inhibitor, ALK5 inhibitor
(SB431542), which prevents TGF-b1-induced R-Smad phos-
phorylation, but not TRAF6, TAK1, or MAP kinase activity (Sor-
rentino et al., 2008). As shown in Figure 2A’s upper panels, the
addition of ALK5 inhibitor to cultures of CD4+ T cells from
Foxp3-GFP mice subjected to TCR-TGF-b stimulation led to
greatly diminished induction of Foxp3-expressing cells (from
57.2% to 6.99%); similarly, as shown in Figure 2A’s lower panels,
CD4+ T cells from B6mice stimulated under the same conditions
and assessed with fluorescent anti-Foxp3 also exhibited
Figure 1. AP-1 Site Located in a Foxp3 Enhancer Region Plays Positive Role on TCR/TGF-b-Induced Foxp3 Gene Expression
(A) Murine CD4+ T cells from Foxp3-GFP mice were stimulated with plate-bound anti-CD3 (10 mg/ml), soluble anti-CD28 (2 mg/ml), and TGF-b (5 ng/ml) with or
without JNK inhibitor (10 mM) for 5 days then collected for flow cytometry analysis.
(B) Schematic diagram of Foxp3 gene (upper) and AP-1: NFAT and Smad3 sites in Foxp3 enhancer I region (lower).
(C) Two different murine T cell lines LBRM (left) and EL4 (right) were transfected with Foxp3 promoter and enhancer I reporter construct (promoter+enhancer I) or
the reporter construct with promoter AP-1 site deletion (promoter+enhancer I promoter AP-1 del) or the reporter construct with enhancer I AP-1 site deletion
(promoter+enhancer I enhancer AP-1 del). Four hours later, cells were split and stimulated with plate-bound anti-CD3 (10 mg/ml) or soluble anti-CD28 (2 mg/ml)
with or without TGF-b (2 ng/ml). Luciferase activity was measured 24 hr later and values were shown as the ratio of firefly luciferase activity to Renilla luciferase
activity from the same well. Data represent four independent experiments. **p < 0.01, compared to intact construct under same stimulation conditions.
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Regulation of Foxp3 via Control of Smad3 Bindinga greatly decreased induction of Foxp3-expressing cells (from
38.2% to 5.51%).
In related studies, we determined the role of TGF-bRI kinase
activity on Foxp3 promoter and enhancer transcriptional activity
with the above described reporter construct. As shown in
Figure 2B, TCR-TGF-b induction of luciferase activity in both
LBRM and EL4 cells was reduced to the degree obtained with
TCR stimulation alone in cells cultured with ALK5 inhibitor, indi-
cating that inhibition of TGF-bRI kinase activity completely abol-
ished the TGF-b effect on Foxp3 gene transcription. Taken
together, these studies show that TGF-b-TGF-bRI signaling via
the R-Smad activation pathway is necessary for TGF-b-medi-
ated Foxp3 transcription. Whether or not TGF-b activation of
the MAPK pathway and the generation of AP-1 is also a neces-
sary function of TGF-b during its induction of Foxp3 expression
is unclear because AP-1 can also be generated by TCR
signaling.ImIdentification of a Foxp3 Silencer Containing a Stat3
Binding Site
TCR-TGF-b induced Foxp3 expression in murine T cells is in-
hibited by several different cytokines (such as IL-6, IL-27, and
IL-21) that have in common the ability to activate Stat3. The
supposition that this signaling component was, in fact, the inhib-
itory factor generated by these cytokines was subsequently sup-
ported by studies showing that inhibition of Foxp3 expression
by IL-27 was partially diminished in cells subject to Stat3 gene
targeting with Stat3-specific siRNA (Huber et al., 2008).
To further explore this possibility, we initially determined TCR
plus TGF-b-induced Foxp3 expression in Stat3-deficient mice.
As shown in Figure 3A, the inhibition of TCR-TGF-b-induced
Foxp3 expression by IL-27 was abolished in Stat3-deficient
CD4+ T cells. Conversely, as also shown in Figure 3A, IL-27 inhi-
bition of TCR-TGF-b-induced Foxp3 expression in CD4+ T cells
from SOCS3-deficient mice, which thus lack an endogenousmunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc. 315
Figure 2. TGF-bRI Kinase Activity Is Essential for TCR-/TGF-b-Induced Foxp3 Expression in Murine T Cells
(A) Purified CD4+ cells from Foxp3-GFP mice (upper panels) or B6 mice (lower panels) were stimulated with plate-bound anti-CD3 (10 mg/ml), soluble anti-CD28
(2 mg/ml), and TGF-b (5ng/ml) with or without ALK5 inhibitor for 4 days, then subjected for flow cytometry analysis.
(B) LBRMor EL4 cells were transfectedwith Foxp3 promoter and enhancer reporter construct, then stimulatedwith plate-bound anti-CD3 (10 mg/ml), soluble anti-
CD28 (2 mg/ml), and TGF-b (2 ng/ml) with or without ALK5 inhibitor for 20 hr. Luciferase activity was measured 24 hr later, and values were shown as the ratio of
firefly luciferase activity to Renilla luciferase activity from the same well. Data are representative of three independent experiments. **p < 0.01, compared to the
luciferase activity without ALK5 inhibitor.
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intact cells: SOC3-deficient cells SOCS3 KO: 51.3% to 4.05%
versus SOCS-intact cells: 40.4% to 8.44%. These data thus
demonstrate that induction of Stat3 activation is key mechanism
of cytokine inhibition of TGF-b-induced Foxp3 expression.
We then extended these findings with an investigation of the
molecular basis of Stat3 suppression of Foxp3 gene transcrip-
tion. An initial computer search of the Foxp3 gene for a Stat3
binding site revealed a canonical site (TTCTCGGAA) located
+4364 to +4372 downstream of the transcription start site.
Then, using the Vista program, we found that this site was
located within a conserved noncoding sequence of the mouse
and human Foxp3 gene that was part of a regulatory region
previously identified (Kim and Leonard, 2007; Tone et al., 2008)
and that could represent a second enhancer region. We, there-
fore, cloned a 973 bp fragment representing this conserved
region and inserted it into the Foxp3 luciferase reporter construct
described above immediately downstream of the first enhancer
region. As shown in Figure 3B, this construct consisted of the
Foxp3 promoter followed by the first enhancer region (enhancer
I) containing the AP-1-NFAT and Smad3 binding sites and the
second enhancer (enhancer II) containing the Stat3 binding site
linked to a luciferase reporter.
With these constructs in hand, we then conducted studies of
the activity of enhancer II in EL-4 cells and LBRM cells, recog-
nizing that, as shown in Figure S2A, these cells constitutively
express substantial levels of pStat3, which in one case is
augmented by IL-6 (EL-4 cells) and in the other by IL-27
(LBRM cells). As shown in Figure 3C, stimulation of cells trans-
fected with the construct that includes enhancer II with TCR-
TGF-b generated a luciferase signal that was decreased
compared to cells transfected with a construct lacking enhancer
II. No additional decrease in luciferase signal was obtained by
adding either IL-6 or IL-27 to the cultures, indicating the basal
amount of pStat3 was sufficient to induce an optimal effect
(data not shown). In complementary studies also shown in316 Immunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc.Figure 3C, stimulation of cells transfected with a construct con-
taining enhancer II with a deletion of the Stat3 binding site gave
rise to an enhanced luciferase signal. In all, these data strongly
suggest that pStat3 binding to a Stat3 binding site in enhancer
II acts as a potent silencer of Foxp3 expression. In addition,
they show that in the absence of Stat3 effects on enhancer II,
the latter has a positive effect on Foxp3 transcription, predicted
by the fact that this area contains binding sites for known positive
transcription factors (Tone et al., 2008).
Retinoic Acid Enhancement of Foxp3 Expression Is
Strictly Dependent on Intact TGF-bRI Kinase Activity
and Smad3
Several groups have recently shown that all-trans retinoic acid
(hereafter called RA) can enhance TCR-TGF-b-induced Foxp3
expression in mouse CD4+ T cells both in vitro and in vivo
(Mucida et al., 2007; Coombes et al., 2007). This effect, as
shown in Figure 4A, leads to expression of Foxp3 in over 95%
of T cells and, thus, is inducing expression in both naive and
mature T cells.
In initial studies of the molecular mechanisms governing RA
enhancement of Foxp3 expression, we determined the effects
of various regulatory factors on such RA enhancement. First,
as shown in Figure 4A, RA enhancement was not diminished in
the presence of JNK inhibitor, indicating that the RA effect
renders the AP-1 effect unnecessary. Second, while the pres-
ence of cyclosporine mildly diminished baseline Foxp3 induction
by TGF-b, it did not affect the enhancement of Foxp3 expression
by RA, indicating that RA functions independently of NFAT.
Third, the negative effect of IL-27 on TCR-TGF-b-induced
Foxp3 expression overrode the positive effect of retinoic acid;
this observation fits with the fact that, as shown in Figure S2B,
the presence of RA has no effect on IL-27 or IL-6 induced phos-
phorylation of Stat3, indicating that the RA effect is independent
of these cytokines and does not enhance Foxp3 expression by
merely blocking a negative signal. In addition, this correlates
Figure 3. Identification of a Foxp3 Silencer Containing a Stat3 Binding Site
(A) Purified CD4+ cells from Stat3fl/fl and Stat3fl/fl; MMTV-Cre mice (left panels) and Socs3fl/fl and Socs3fl/fl; MMTV-Cre mice (right panels) were stimulated with
plate bound anti-CD3 (10 mg/ml), soluble anti-CD28 (2 mg/ml), and TGF-b (5 ng/ml) with or without IL-27 (20 ng/ml) for 4 days, then collected for Foxp3 staining and
subjected to flow cytometry analysis.
(B) Alignment of human andmouse Foxp3 enhancer II region containing stat3 binding site (up) and the structure of Foxp3 promoter and enhancer I and enhancer II
(contains stat3 binding site) reporter construct.
(C) Murine T cell line LBRM was transfected with Foxp3 promoter and enhancer I reporter construct or Foxp3 promoter and Enhancer I and enhancer II reporter
constructor Foxp3promoterandEnhancer I andenhancer II reporter constructwith stat3bindingsitedeletion thenstimulatedwithplateboundanti-CD3 (10mg/ml),
soluble anti-CD28 (2 mg/ml), andTGF-b (2 ng/ml). Luciferase activity wasmeasured 24 hr later and valueswere shownas the ratio of firefly luciferase activity/Renilla
luciferase activity from the same well. Data are representative of four independent experiments. *p < 0.05, **p < 0.01, compared to intact construct under same
stimulation conditions.
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of Stat3 and Stat5 (Elias et al., 2008). Fourth, as shown in
Figure S3A, the RA enhancing effect was not affected by the
presence of a large number of cytokines other than IL-27 and
IL-6, again emphasizing that the effect was not because of posi-
tive or negative effects of cytokine regulation of Foxp3 expres-
sion; importantly, as shown in Figure S3B, this was also true of
IL-4, which suppresses baseline induction of Foxp3 by TCR-
TGF-b, but not RA enhancement of baseline induction. Finally,
as also shown in Figure 4A, the positive effect of RA is completely
dependent on TGF-bRI kinase activity because the percentage
of Foxp3+ cells decreased to baseline (3.19%) if cells were stim-
ulated with TCR-TGF-b and RA in the presence of ALK5 inhibitor.
To further address the mechanism of RA enhancement of
Foxp3 expression, we subjected CD4+ T cells from Smad3-defi-
cient mice to TCR-TGF-b stimulation with and without RA. As
shown in Figure 4B, Foxp3 induction by TCR-TGF-b was greatly
diminished in B6 Smad3-deficient mice, and more importantly,ImRA exhibited virtually no enhancement of TCR-TGF-b-induced
Foxp3 in such mice. As shown in Figure S4A, virtually identical
results were obtained with cells from BALB/c Smad3-deficient
mice, indicating that the results were not strain specific. These
data clearly indicate that both TGF-b induction of Foxp3 as
well as the positive effect of RA on such induction is largely
dependent on Smad3.
The Enhancement of TCR-TGF-b-Induced Foxp3
Transcription by RA Is Not Because of Increased Smad3
Phosphorylation under Optimal TGF-b Induction
Conditions
Based on the above results, it seemed possible that TCR-TGF-
b-induced Foxp3 transcription is enhanced by RA because RA
enhances the phosphorylation of Smad3 and thereby facilitates
Smad3 translocation into the nucleus, as already suggested in
a previous study (Xiao et al., 2008). To explore this possibility,
we first determined Foxp3 expression in CD4+ T cells exposedmunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc. 317
Figure 4. The Positive Effect of Retinoic Acid on Foxp3 Expression Completely Depends on Intact TGF-bRI Kinase Activity and Smad3
(A) Purified CD4+ cells from Foxp3-GFP mice were stimulated with plate-bound anti-CD3 (10 mg/ml), soluble anti-CD28 (2 mg/ml), and TGF-b (5 ng/ml) with or
without retinoic acid (100 nM) and JNK kinase inhibitor (10 mM), cyclosporine A (20 nM), IL-27 (20 ng/ml), or ALK5 inhibitor (5 mM) for 4 days, then collected
for flow cytometry analysis.
(B) Purified CD4+ cells from B6-WT littermate mice and B6-Smad3 knockout were stimulated with plate-bound anti-CD3 (10 mg/ml), soluble anti-CD28 (1 mg/ml),
TGF-b(5 ng/ml), or RA (100 nM) with or without ALK5 inhibitor (2.5 mM) for 4 days. Cells were collected and stained with APC anti-Foxp3 (eBioscience), then sub-
jected to flow-cytometric analysis.
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absence of RA. As shown in Figure 5A, TGF-b induction of stable
baseline levels of Foxp3+ cells was unchanged over a wide range
of TGF-b concentrations (1 ng/ml to 40 ng/ml) and was dimin-
ished only at a very low (0.1 ng/ml) TGF-b concentration. Further-
more, the addition of RA enhanced the number of Foxp3+ cells to
an equal degree over the range of TGF-b concentrations that
gave rise to the stable baseline levels of Foxp3, and reduced
RA enhancement was only seen at the low TGF-b concentration
(0.1 ng/ml) that gave rise to low baseline Foxp3 expression.
These data show that RA enhancement is weak until a baseline
level of TCR- and TGF-b-induced Foxp3 expression is reached
and suggest that the main RA effect occurs after baseline
TCR- and TGF-b induction involving NFAT-AP-1 has occurred.
In further studies along these lines, we assessed the amount of
pSmad3 induced by different concentrations of TGF-b in the
presence and absence of RA. As shown in the immunoblot
depicted in Figure 5B (left panel) and the density analysis of
this blot in Figure 5B (right panel), addition of RA was accompa-
nied by increased phosphorylation of Smad3 only in the pres-318 Immunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc.ence of a low concentration of TGF-b (0.1 ng/ml); in contrast,
over a wide range of higher TGF-b concentrations (1–20 ng/
ml), addition of RA was unaccompanied by increased phosphor-
ylation. In assessing the significance of the enhancement at
0.1 ng/ml of TGF-b, it should be noted that at this concentration,
both baseline (TGF-b only) and RA enhanced (TGF-b plus RA)
Foxp3 levels were lower than those obtained at higher TGF-b
concentrations, which, in fact, reached a stable plateau at
a TGF-b concentration of 1 ng/ml. In addition, at the 0.1 ng/ml
TGF-b concentration, the amount of pSmad3 in the presence
of RA was as high as that obtained at higher TGF-b concentra-
tions, indicating that no additional phosphorylation is required
to achieve a higher level amount of Foxp3 expression with higher
concentrations of TGF-b. Finally, as shown in Figure S4B, we
found, as did Nolting et al. (2009), that RA induced increased
amounts of Smad3 protein in the absence of increased Smad3
phosphorylation after 12 hr of culture without any effect on
Foxp3 expression; this could explain the apparent increase in
phosphorylation induced by RA in the presence of low concen-
trations of TGF-b because, under these conditions, RA may be
Figure 5. The Enhancement of RA on TCR/TGF-b-Induced Foxp3 Transcription Is Not Because of Increased Smad3 Phosphorylation
(A) Purified CD4+ cells from Foxp3-GFP mice were stimulated with plate-bound anti-CD3 (10 mg/ml), soluble anti-CD28 (2 mg/ml), and TGF-b at different concen-
trations as indicated with or without retinoic acid (200 nM) for 4 days, then collected for flow cytometry analysis.
(B) Purified CD4+ cells from B6mice were stimulated with TGF-b at different concentrations as indicated, with or without retinoic acid (500 nM) for 2 hr. Cells were
collected, and cell lysates were prepared and subjected to immunoblot (left). Intensity of bands wasmeasured using NIH Image software and showed as the ratio
between p-Smad3 and Smad3 from the same sample (right). Data are representative of two independent experiments.
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phosphorylation (whereas, at higher TGF-b concentrations, RA
induction of Smad3 protein is redundant). Overall then, whereas
increased Smad3 phosphorylation in the presence of RAmay be
a cause of RA enhancement at suboptimal TGF-b concentra-
tions, once baseline TCR- and TGF-b induction of Foxp3 is ob-
tained (i.e., at the usual inducing concentrations of TGF-b), RA
enhancement of Foxp3 induction is not because of increased
Smad3 phosphorylation.
Retinoic Acid Directly Regulates Foxp3 Promoter and
Enhancer Activity
To study the mechanism underlying RA regulation of Foxp3
expression, we analyzed RA effects on the Foxp3 reporter
construct expressed in LBRM and EL4 cells as described above.
Our study was based on the knowledge that the cellular effects
of RA are mediated through its ligation of RAR and/or RXR fol-
lowed by translocation of these factors to the nucleus and
specific binding to gene target sites (Mangelsdorf and Evans,
1995). Indeed, as shown in Figure 6A, we found two RAR-RXRImbinding sites in the Foxp3 gene, one located in the Foxp3
promoter at 310 to 306 and one in enhancer I at +2611 to
+2618. This mandated that we utilize cells transfected with
a luciferase reporter construct containing both promoter and
enhancer I components containing these sites in studies of RA
regulation of the Foxp3 gene.
In initial studies, we determined luciferase output by both
transfected EL-4 and LBRM cells subjected to TCR-TGF-b stim-
ulation with or without RA at different concentrations. As shown
in Figure 6B, addition of RA enhanced the Foxp3 promoter-
enhancer I construct luciferase activity in a dose-dependent
manner. Next, we cultured cells with the same stimulants but
in this case used cells transfected with constructs with deleted
RAR-RXR binding site in the promoter or the enhancer regions
or in both regions. As shown in Figure 6C, deletion of the RAR-
RXR binding site in the promoter resulted in a small decrease
in reporter signal, whereas deletion of the binding site in
enhancer I led to a large decrease in the luciferase signal; in addi-
tion, deletion of both binding sites led to an additive decrease to
a level of transcription that was only marginally higher than thatmunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc. 319
Figure 6. Retinoic Acid Directly Regulates
Foxp3 Promoter and Enhancer Activity
(A) Location of two RAR-RXR binding sites in
Foxp3 promoter and enhancer I regions.
(B) LBRM (left) or EL4 (right) cells were transfected
with a Foxp3 promoter and enhancer I reporter
construct and stimulated with plate-bound anti-
CD3 (10 mg/ml), soluble anti-CD28 (2 mg/ml) plus
TGF-b (2 ng/ml), and retinoic acid at a series of
concentration as indicated. Luciferase activity
was measured 24 hr later, and values were shown
as the ratio of firefly luciferase activity to renilla
luciferase activity from the same well. Data are
representative of two independent experiments.
**p < 0.01, compared to the luciferase activity
without RA.
(C) EL4 cells were transfected with Foxp3
promoter and enhancer I reporter construct with
deletion of the RAR-RXR binding site in either the
promoter region or enhancer region (as indicated
in A) or both and then stimulated with plate-bound
anti-CD3 (10 mg/ml), soluble anti-CD28 (2 mg/ml),
and TGF-b (2 ng/ml) with or without retinoic acid
(500 nM) as indicated. (ProRAR-RXR del,
promoter RAR-RXR deletion; EnhRAR-RXR del,
enhancer I RAR-RXR deletion; Pro+Enh RAR-
RXR del, promoter+enhancer I RAR-RXR dele-
tion). Luciferase activity was measured 24 hr later,
and values were shown as the ratio of firefly lucif-
erase activity to Renilla luciferase activity from the
same well. Data are representative of three inde-
pendent experiments. **p < 0.01, compared to
intact construct under same stimulation condi-
tions.
Immunity
Regulation of Foxp3 via Control of Smad3 Bindingobtained by TCR-TGF-b stimulation in the absence of RA. We
conclude that whereas the transcriptional activity of the
enhancer I RAR-RXR binding site is greater than the activity of
the promoter binding site, the latter is not trivial because binding
of RA to both the promoter and enhancer sites is necessary for
the full effect of RA on TGF-b -induced Foxp3 transcription.
In further studies along these lines we conducted reporter
construct studies in purified CD4+ T cells rather than cell lines
to verify that the above results would also obtain in a more phys-
iological intracellular milieu. Accordingly, purified primary CD4+
T cells were transfected with a reporter construct containing
both promoter and enhancer I and enhancer II elements and
then assayed for luciferase activity under various conditions.
As shown in Figure S5A, TCR activation of the cells in the pres-
ence of TGF-b led to increased luciferase activity compared to
TCR activation alone, which was further augmented by the addi-
tion of RA. In addition, this increase in luciferase activity was
completely reversed by the addition of anti-IL-27. The latter
inhibitory effect was not seen in the cell line studies because of
high baseline cytoplasmic pStat3 amounts in the cell line cells
that obviate the effect of Stat3 activation by IL-27 signaling
(see Discussion below). In a parallel set of studies, the cells
were transfected with a promoter-enhancer I reporter constructs
in which the enhancer I RAR-RXRwas either intact or deleted. As
shown in Figure S5B, the construct with the deleted RAR-RXR
site exhibited complete loss of luciferase acivity in cells stimu-
lated by TGF-b plus RA. Taken together, these studies in primary
CD4+ T cells corroborate those with cell lines and verify that RA320 Immunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc.directly regulates Foxp3 expression via RAR-RXR binding to an
enhancer site. Interestingly, the importance of RAR-RXR binding
to Foxp3 expression in the primary cells was somewhat greater
than in the cell lines, suggesting that in primary cells Smad3
binding to the enhancer is more dependent on RAR-RXR than
in cell lines.
RA Increases Histone Acetylation at the Enhancer I
Region Containing the NF-AT-Smad3 Binding Sites
Given the strict dependence of the RA enhancing effect on
Smad3 activity and the proximity of the RAR-RXR binding site
to the Smad3 binding site, it seemed likely that the mechanism
of the enhancing effect might be because of a direct effect of
RA on Smad3 transcriptional activity. To test this hypothesis,
we first determined if RAR-RXR physically interacted with
Smad3. Accordingly, we subjected CD4+ T cells subjected to
TCR-TGF-b stimulation in the presence of RA to coimmunopre-
cipitation studies using several relevant antibodies in a variety of
combinations but could find no evidence of RAR-RXR-Smad3
interaction (data not shown). Next, we sought to determine
whether RAR-RXR could increase the accessibility of the
enhancer I to transcription factors. Because this region contains
no CpG sequences, we chose to do this by performing ChIP
studies to assess the level of histone acetylation in these regions
rather than by performing methylation studies. As shown in
Figure 7A, with respect to the enhancer I region, stimulation of
CD4+ T cells with anti-CD3/CD28 was associated with little or
no histone acetylation, stimulation with TCR-TGF-b was
Figure 7. RA Increases Histone Acetylation
at the Enhancer Region Containing NF-AT-
Smad3 Binding Sites and Facilitates
Increased Smad3 Binding to Enhancer
(A) Purified CD4+ cells from B6 mice were stimu-
lated with plate-bound anti-CD3 (10 mg/ml),
soluble anti-CD28 (2 mg/ml), and TGF-b (5 ng/ml)
with or without retinoic acid (200 nM) for 48 hr.
CHIP assay was performed using anti-acetyi
histone H4 antibody or rabbit IgG. Precipitated
chromatins were subjected to real-time PCR using
primers targeting enhancer I region (upper) or
promoter region (lower). Values were shown as
the percentage of corresponding input. Data are
representative of three independent experiments.
(B) Purified CD4+ cells from B6 mice were treated
as in (A) with or without IL-27 (20 ng/ml) for 2 hr.
CHIP assay was performed using anti-Smad3
antibody or rabbit IgG. Precipitated chromatins
were subjected to real-time PCR using primers
targeting enhancer I region. Values were shown as the percentage of corresponding input. Data are representative of two independent experiments.
(C) Purified CD4+ cells from B6 mice were stimulated with plate-bound anti-CD3 (10 mg/ml), soluble anti-CD28 (2 mg/ml), and TGF-b (5 ng/ml) with or without JNK
kinase inhibitor (10 mM) for 2 hr. CHIP assay was performed using anti-Smad3 antibody or rabbit IgG as described in (B).
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tion with TGF-b plus RA was associated with a high level of
histone acetylation. In contrast, RA stimulation or TGF-b plus
RA increased acetylation only slightly in the promoter region.
These data indicate that themain effect of RA on the accessibility
of transcription factors to gene target sites was in the enhancer 1
region.AP-1 and RA Enhance, whereas IL-27 Inhibits, pSmad3
Binding to Enhancer I
In next series of studies, we first sought to determine if the
increased accessibility of the Smad3 binding region induced
by RAR-RXR noted above results in an actual increased binding
of pSmad3 to this region. To this end, we performed Smad3-
specific ChIP assays on TCR-TGF-b-stimulated CD4+ T cells
stimulated in the presence and absence of RA. As shown in
Figure 7B, RA stimulation of cells was associated with markedly
increased pSmad3 binding in the enhancer I region which
contains the pSmad3 binding site.
We then sought to determine if binding of pSmad3 to the
enhancer I region in CD4+ T cells is affected by IL-27 signaling
that inhibits both TGF-b- and TGF-b plus RA-induced upregula-
tion of Foxp3 expression through activation of Stat3 and, in turn,
the subsequent activation of the gene silencing site in enhancer
II. Accordingly, Smad3-specific ChIP assays were performed on
CD4+ T cells stimulated with TGF-b or TGF-b plus RA in the pres-
ence and absence of IL-27. As shown in Figure 7C, while RA
enhanced pSmad3 binding to the enhancer I site, addition of
IL-27 to the culture inhibited pSmad3 binding both in cells stim-
ulated by TGF-b alone and with TGF-b and RA. This is in agree-
ment with data showing that IL-27 downregulates both TGF-b
and TGF-b plus RA enhancement of Foxp3 expression.
Having thus demonstrated that both RA and IL-27 modify
TCR + TGF-b induced Foxp3 expression via a common mecha-
nism, i.e., regulation of pSmad3 binding to enhancer I, we
recalled an earlier finding that RA reduces the need for AP-1
binding to enhancer I. This suggested that AP-1 (or the NFAT-
AP-1 complex) acts primarily to increase pSmad3 binding toImenhancer 1. To explore this possibility, we performed ChIP
assays of pSmad3 binding to enhancer I in primary CD4+
T cells stimulated with TCR- and TGF-b in the presence and
absence of JNK inhibitor. As shown in Figure 7C, the presence
of the JNK inhibitor does indeed reduce pSmad3 binding. Thus,
we conclude that not only RA and cytokine modification of
Foxp3 expression occur via regulation of pSmad3 binding, but
also that baseline Foxp3expressiondependson thismechanism.Blockade of pSmad3 Binding to Its Binding Site in
Enhancer I Compromises both TGF-b and TGF-b-RA
Induction of Foxp3 Expression
The above studies showing that TGF-b and TGF-b/RA induction
of Foxp3 expression depends on generation of pSmad3 and its
efficient binding to a site in enhancer I predicts that inhibition
of pSmad3 binding to its enhancer site would result in reduced
TGF-b- and TGF-b-RA-induced Foxp3 expression not only in
cells lacking Smad3, but also in cells lacking Smad3 binding
sites in enhancer 1. In initial studies to examine this prediction
we transfected purified CD4+ T cells from Foxp3-GFP knockin
mice with Alexa647-labeled oligonucleotides having a sequence
identical to the Smad3 binding site in Foxp3 enhancer I which
thus act as ‘‘decoy’’ oligos that block the binding of Smad3 to
this enhancer site. In a parallel study we transfected the same
cells with an oligonucleotide having a sequence identical to
a consensus Smad3 binding sequence (Schneiders et al.,
2005) to determine if blockade of the Foxp3 site was relative
specific and blockade of Smad3 binding sites in other parts of
the genome would have relatively little effect on Foxp3 expres-
sion. In parallel with these latter studies we determined the effect
of Foxp3- specific and consensus sequence blocking oligonu-
cleotides on expression of a luciferase reporter gene driven by
a PAI promoter containing three consensus sequence of
Smad3 binding site in Hep3B cells (Wrana et al., 1992). Oligonu-
cleotides with a ‘‘scrambled’’ sequence were employed as
controls and transfected cells were identified by labeling with
Alexa647. As shown in Figure S5C, TGF-b- and TGF-b plus
RA-induced Foxp3 expression in the presence of the scrambledmunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc. 321
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absence of any decoy, whereas such expression in the presence
of the Foxp3-specific Smad3 decoy was substantially reduced.
In contrast, as also shown here, the blocking effect achieved
with the consensus Smad3 decoy was substantially less and,
as shown in Figure S5D, the Smad3 Foxp3-specific Smad3
decoy led to only marginal blocking of the consensus Smad3
sites. These studies provide further data supporting the concept
that Smad3 binding to its binding site in the Foxp3 enhancer I is
indeed an important component in TGF-b-RA induction of Foxp3
transcription, particularly in view of the fact that the Foxp3-
specific Smad3 blocking decoy had only a marginal effect on
Smad3 binding to consensus sequences elsewhere in the
genome. In addition, inasmuch as these studies were conducted
in primary CD4+ T cells with an intact Foxp3 gene, they show that
Smad3 binding to its enhancer site and subsequent enhance-
ment of Foxp3 transcription occurs under physiologic condi-
tions.
In an second study of the prediction above regarding the
consequences of inhibition of pSmad3 binding to its enhancer
site, we determined the effects of deletion of the Smad3 binding
site on a luciferase reporter construct driven by an intact Foxp3
gene fragment containing the Foxp3 promoter and enhancer
regions. This fragment was derived from a BAC clone and con-
sisted of 5.8kb of DNA extending from a site approximately 1
kb upstream of the Foxp3 transcription start site (containing
the bulk of the Foxp3 promoter) to a site 4.8kb downstream of
transcription start site (containing both enhancer I and enhancer
2 regions discussed above). As shown in Figure S6A, TGF-b and
TGF-b plus RA had the expected enhancing effects on the lucif-
erase signal in both EL4 and LBRM cells. Perhaps more impor-
tantly, as shown in Figure S6B (left panel), the same construct
containing a deletion of the Smad3 binding site exhibited a signif-
icantly reduced signal with both TGF-b and TGFb plus RA stim-
ulation. In addition, in the absence of the Smad3 binding site
there was no significant increase in luciferase signal in cells stim-
ulated by TGF-b plus RA as compared to those stimulated with
TGF-b alone. Thus, these studies corroborate the studies
utilizing decoy oligonucleotides described above in that they
show that RA enhancement of Foxp3 transcription is in fact
dependent on Smad3 binding, and that such dependence
occurs in the context of an intact Foxp3 gene fragment.
In related studies we also utilized the intact (Bac) Foxp3 con-
truct described above to verify effects of AP-1 and Stat3 binding
site deletions previously studied with more conventional non-
Bac reporter constructs. As shown in Figure S6B (right panel),
deletion of the enhancer I AP-1 site led to decreased signal
in TGF-b plus RA stimulated cells but not to decreased signal
in TGF-b-stimulated cells consistent with previous studies
showing the lack of involvement of the enhancer I AP-1 site in
RA enhancement; in addition, deletion of the enhancer II Stat3
binding site led to increased signal again reflecting the downre-
gulatory effect of this site.
In Vivo Verification of the Importance of Smad3 to Foxp3
Expression
Finally, we evaluated the role of Smad3 in the in vivo generation
of Foxp3+ T cells. Here, we took advantage of previous work in
which we showed that intra-nasal administration of a ‘‘tet-on’’322 Immunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc.TGF-b plasmid (pTet-on-TGF-b1 that induces high amounts of
TGF-b production in lamina propria cells of mice with experi-
mental colitis (DSS-colitis), the latter necessary to activate
CMV promoters in the plasmid) (Kitani et al., 2003); thus, admin-
istration of this plasmid recreates conditions under which Foxp3-
expressing cells are induced in the intestine, particularly under
the influence of endogenous retinoic acid production. Accord-
ingly, we administered this plasmid to wild-type and Smad3-
deficient mice by an intranasal route (along with parenteral
doxycycline). As shown in Figure S7, plasmid administration
induced a striking increase in Foxp3 expressing cells in both
colon and MLNs of wild-type mice, whereas in Smad3 KO, it
had only a marginal effect, which could be attributable to effects
of the induced inflammation on natural (nTreg) Foxp3+ cells.
Thus, Smad3 is a necessary component of TGF-b-induced
Treg (iTreg) development both in vitro and in vivo.
DISCUSSION
The regulation of Foxp3 transcription is a multifaceted process
that probably reflects the necessity of the immune system to
fine-tune regulatory T cell function under a vast variety of circum-
stances. In the present study, we focused on regulation of Foxp3
transcription occurring in relation to Tregs induced in the periph-
eral lymphoid system under the influence of TGF-b; other
factors, some overlapping with those discussed here, may be
involved in ‘‘natural’’ Tregs developing in the thymus (Liu et al.,
2008).
The data gathered in these studies suggest that regulation of
Foxp3 transcription and regulatory T cell development in the
peripheral lymphoid tissues is best understood as a two stage
process consisting of an initial stage inwhich Foxp3 transcription
was initiated by T cell receptor stimulation and TGF-b signaling
and a second stage in which this initial transcription was either
enhanced by retinoic acid (RA) or inhibited by proinflammatory
cytokines. Key insights into the molecular events occurring
during this stage has come from a previous study by Tone
et al. who defined the transcriptional activity of a 1.8 kb
Foxp3 promoter fragment and a conserved downstream
enhancer (located at +1988 to +2738). In these studies, it was
shown with reporter assays that the Foxp3 promoter appeared
to have a surprisingly little role in Foxp3 transcription and the
main control site was the intronic enhancer (enhancer I), which
contained both NFAT and Smad3 binding sites. This conclusion
arose from the fact that deletion of either NFAT or Smad3 binding
sites led to compromised TCR-TGF-b-induced Foxp3 transcrip-
tion. More recently, however, this group has provided evidence
that during TCR-TGF-b-induced Foxp3 transcription, the Foxp3
promoter binds c-Rel, p65, and NFATc2 to a site at which a ‘‘en-
hanceosome’’ complex is formed, which ultimately contains
transcription elements such as Smad3 and Creb recruited from
enhancer regions. Thus, the promoter does in fact play a major
role in Foxp3 transcription (Ruan et al., 2009).
In our initial studies, we expanded on these findings by
demonstrating that TGF-b induction of Foxp3 in naive T cells
was greatly inhibited by a JNK inhibitor. This implied the exis-
tence of an AP-1 binding site in the Foxp3 promoter-enhancer
region, and indeed, we identified a sequence ordinarily consid-
ered a ‘‘weak’’ (or partial) AP-1 binding site in the enhancer
Immunity
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complemented three additional AP-1 sites in the promoter previ-
ously identified by Mantel et al. (2006). In subsequent studies
employing a luciferase reporter system, we confirmed the func-
tional significance of AP-1 binding by showing that deletion of
the AP-1 site in the enhancer, but not the most 50 AP-1 site
in the promoter, greatly decreased Foxp3 promoter-enhancer
function. However, we could not exclude the possibility that
the other two AP-1 sites located at promoter region might
compensate the AP-1 site or are required to act in tandem.
The importance of AP-1 to TGF-b-induced Foxp3 expression is
probably related to its role in facilitating the function of NFAT,
a TCR-induced transcription factor which, as mentioned above,
has been shown to be essential for such expression. In further
studies of the role of AP-1 in Foxp3 expression, we found that
treatment of CD4+ T cells with a JNK inhibitor led to decreased
Smad3 binding to enhancer I as determined by ChIP analysis.
This suggests that one function of AP-1 and by inference, the
NFAT-AP-1 complex, in TGF-b-induced Foxp3 expression is to
enhance Smad3 binding. Taken together, these findings intro-
duced the concept that a central feature of control of TGF-b-
induced Foxp3 expression is the regulation of Smad3 binding
to enhancer I.
In further studies supporting this latter conclusion, we first
showed that cells from Smad3-deficient mice cannot be induced
to express Foxp3 when stimulated in the presence of either
TGF-b alone or TGF-b plus RA. Because this result was contrary
to that reported in a recent study by Nolting et al., in which the
latter authors reported that cells from Smad3-deficient mice
could be induced to express Foxp3 (Nolting et al., 2009), we per-
formed multiple studies of cells from two independent strains of
Smad3-deficient mice, one on a B6 and another on a BALB/c
background (the latter identical to that used by Nolting et al.).
Second, we showed that inhibition of Smad3 binding to its target
sequence in enhancer I with the addition of a decoy oligonucle-
otide that competes with the target sequence for Smad3 binding
leads to substantial inhibition of both induction of Foxp3 by
TGF-b alone or TGF-b plus RA. Importantly, the Foxp3-specific
decoy oligo used in this study had only a marginal ability to block
consensus Smad3 sequences, suggesting that the blocking
effect was not because of blocking of Smad3 effects on other
parts of the genome. This study, conducted in CD4+ T cells
with an intact and endogenous Foxp3gene, rather than a reporter
construct, provides strong evidence that for Foxp3 induction to
occur, not only must activated Smad3 be generated but also
that activated Smad3 must bind to a site in the Foxp3 enhancer
I. Finally, we performed in vivo studies of Smad3-deficient mice
in which we showed that induction of Foxp3+ cells in the colons
or MLN of wild-type mice with mild DSS colitis by nasal admin-
istration of a plasmid inducing high levels of TGF-b is greatly
impaired in Smad3-deficient mice. This result showed that
Smad3 activity is necessary for induced Foxp3 induction under
in vivo conditions as well as under in vitro conditions. Taken
together, these various studies establish rather definitively that
induced Foxp3 expression is a Smad-dependent event.
Recently, it has been shown that retinoic acid (RA) produced
by antigen-presenting cells, particularly in mucosal tissues,
enhances TCR-TGF-b-induced expansion of Foxp3 regulatory
cells; however, despite considerable investigation, the mecha-Imnism of this RA effect remained unclear. One possibility sug-
gested by Kretschmer and his colleagues (Kretschmer et al.,
2008) was that RA reverses the negative effect of AP-1 (induced
by costimulation) on Foxp3 expression; this possibility, however,
is unlikely in view of the positive effect of AP-1 on Foxp3 expres-
sion shown here. A second possibility is that RA promotes
Smad3 phosphorylation and, thus, Smad3 translocation to the
nucleus; in addition, RA downregulates receptors of inhibitory
cytokines (Xiao et al., 2008). However, we found in extensive
studies in which cells were stimulated with a wide range of
TGF-b concentrations that RA induces Smad3 phosphorylation
only when low (suboptimal) TGF-b concentrations are present,
and under these conditions, such induction may be more
apparent than real because RA induces Smad3 and, thus,makes
more Smad3 available for TGF-b-induced phosphorylation; thus,
the weight of evidence suggests that while RA enhancing effects
could be explained by induction of increased Smad3 phosphor-
ylation at low TGF-b concentrations, this does not explain its
enhancing effects at TGF-b concentrations likely to obtain at
tissue sites. In addition, we also found that RA had no effect
on the ability of inhibitory cytokines to induce pStat3, so there
is no evidence to support the view that RA augmentation occurs
through effects on cytokine inhibition. A third possibility, sug-
gested by Hill et al. (2008), was that the RA effect is indirect
because of its ability to counter the inhibiting effect of cytokines
such as IL-4, IL-21, and IFN-g produced by nonregulatory,
mature T cells (Hill et al., 2008). One problem with this possibility
is that, as shown here, while IL-4 does indeed downregulate
TGF-b-induced baseline Foxp3 expression, it has little if any
effect on RA augmentation of such expression. Overall, while it
seems possible that RA augmentation can be because, espe-
cially in vivo, of indirect effects on inhibitory cytokine secretion,
the extensive data here documenting that RA influences Foxp3
transcription would argue that its augmenting effect is mainly
because of a direct effect on Foxp3 promoter-enhancer activity.
In our search for another explanation of the RA enhancing
effect, we focused on the exquisite dependence of RA augmen-
tation of TGF-b-induction of Foxp3 on Smad3 mentioned above
and were, thus, led to the hypothesis that the RA effect occurs
because it increases the level of binding of pSmad3 to its binding
site in enhancer I. In fact, all of the findings reported here are in
support of this view. First, the addition of RA to cultures of
T cell lines bearing Foxp3 luciferase reporter constructs consis-
tently gave rise to an increased luciferase signal; this suggested
that the transcription factor resulting from RA signaling, RAR-
RXR, was indeed having a direct effect on Foxp3 promoter and
enhancer activity. Second, we found that the Foxp3 gene has
at least two potential RAR-RXR binding sites: one in the
promoter and another in enhancer I very close to the AP-1
binding site. Furthermore, deletion of the RAR-RXR binding
site in enhancer I (close to the AP-1 binding site) led to a major
reduction in the RA enhancing activity and deletion of both the
RAR-RXR binding sites in both in enhancer I and in the promoter
led to a virtual complete loss of RA enhancer activity; impor-
tantly, with respect to the RAR-RXR binding site in enhancer I,
this result was verified by luciferase reporter assays conducted
in primary CD4+ T cells. Third, while addition of TGF-b alone to
cultures of CD4+ T cells led to increased histone acetylation at
the enhancer I site, addition of both RA and TGF-b led tomunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc. 323
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that RA greatly increases the accessibility of this site to transcrip-
tion factors. Finally, in ChIP assays, addition of RA to TCR-
TGF-b-stimulated cell cultures greatly increased binding of
pSmad3 to its binding site in enhancer I. Thus, while AP-1
(or more probably NFAT-AP-1) controls initial pSmad3 binding
to enhancer 1 and a basal level of Foxp3 transcription, it was
evident from these studies that RA controls a second,
augmented level of binding and, thus, a higher level of Foxp3
transcription. Finally, it should be noted that the presence of
RA greatly diminished the negative effect of JNK inhibition on
TCR- and TGF-b-induced Foxp3 expression. We attribute this
to the possibility that RAR-RXR binding in enhancer I to a great
extent obviates the need for NFAT-AP-1 augmentation of
pSmad3 binding.
In the present studies, we also investigated the inhibition
of TCR- and TGF-b induction of Foxp3 or such induction
augmented by RA or by cytokines such as IL-27 and IL-6, which
induce Stat3 activation and showed in such that inhibition was
abolished in Stat3-deficient cells and augmented in SOC3-defi-
cient cells; we thereby verified the view that had previously been
proposed that inhibition by these cytokines was mediated by
Stat3 (Huber et al., 2008). It was evident in these studies that
IL-27 inhibited both baseline and RA-augmented TCR-TGF-b-
induced Foxp3 expression. This, however, does not obtain for
IL-4, a cytokine that inhibits baseline but not RA-augmented
TCR- and TGF-b-induced Foxp3 expression and which induces
pStat6 rather than pStat3.
In dissecting the mechanism of IL-27-induced inhibition, we
first sought a binding site for Stat3 and indeed found such
a site in a second conserved enhancer region downstream of
enhancer I, which we call enhancer II. The investigation of the
function of this site with our reporter system was somewhat indi-
rect because the cells used for transfection of the reporter
constructs both produced substantial amounts of endogenous
pStat3, thus precluding the use of these cells as targets of cyto-
kine inhibition via induction of activated Stat3. We overcame this
difficulty by determination of the effect of the deletion of the
pStat3 site on the reporter activity of a construct containing
the Foxp3 promoter, enhancer I, and enhancer II in tandem
recognizing that the effect of deletion would be because of
loss of pStat3 signaling by endogenous pStat3 and the latter
would be a ‘‘proxy’’ for cytokine-induced pStat3. We found the
deletion of the pStat3 binding site did in fact lead to augmenta-
tion of the luciferase reporter signal, indicating that Stat3 binding
was acting as a potent gene silencer that affects both basal and
augmented TCR-TGF-b-induced Foxp3. Interestingly, deletion
of the pStat3 binding site in enhancer II generated a signal that
was augmented with respect that generated by a construct
that did not contain enhancer II. This revealed that in the absence
of the effect of pStat3 binding, enhancer II did actually function
as an enhancer, possibly via the binding of other endogenous
positive factors to this region such as CREB-ATF (Kim and Leo-
nard, 2007). In a final and critical series of studies of IL-27 inhibi-
tion of TCR-TGF-b-induced Foxp3 expression, we showed that
in CD4+ T cells, such inhibition is associatedwith greatly reduced
Smad3 binding to enhancer I whether or not the latter is
augmented by RA. Thus, whereas the molecular mechanism of
cytokine inhibition is different from that of RA augmentation,324 Immunity 33, 313–325, September 24, 2010 ª2010 Elsevier Inc.both operate through a final common pathway, namely the regu-
lation of Smad3 binding to enhancer I.
EXPERIMENTAL PROCEDURES
Mice
Specific pathogen-free, female C57BL/6 mice were purchased from the Jack-
son Laboratory (Bar Harbor, ME). Foxp3-IRES-GFP knockin mice on a C57BL/
6 background were obtained fromM. Oukka (Brigham andWomen’s Hospital,
BostonMA). Stat3fl/fl and Stat3fl/fl; MMTV-Cremice and Socs3fl/fl and Socs3fl/fl;
MMTV-Cre mice were kind gifts from Dr. J. J. O’Shea (Molecular Immunology
and Inflammation Branch, NIAMS/NIH). Smad3 knockout mice on a C57BL/6
background were kind gifts from Dr. S. Wahl (Oral Infection and Immunity
Branch, NIDCR/NIH). These mice were studied at 8–14 weeks of age. Animal
use adhered to National Institutes of Health Laboratory Animal Care Guide-
lines.
Cell Lines
A mouse T lymphoma cell line LBRM-33 clone 4A2 (LBRM) was obtained from
ATCC. EL4 clone LAF cell (EL4) was a kind gift from Dr. M. Tone, University of
Pennsylvania. Both cell lines were maintained in IMDM supplemented with 5%
FCS, 100 U/ml penicillin, and 100 mg/ml streptomycin.
In Vitro Cell Stimulation
Murine CD4+ T cells were cultured in 1 ml of IMDM supplemented with 10%
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 53 103 Mmercaptoe-
thanol. Cells were stimulatedwith plate-bound anti-CD3 (10 mg/ml) and soluble
anti-CD28 (2 mg/ml). Cytokines, neutralizing antibodies, and other reagents
were added to cultures at the following concentrations: rTGF-b1 (5 ng/ml,
R&D), IL-27 (20 ng/ml, Peprotech), cyclosporin A (CsA) (20 nM), ALK5 inhibitor
(5 mM, EMD), and JNK kinase inhibitor (5 mM, EMD 420116). Neither CsA nor
the ALK5 or JNK kinase inhibitors affected cell viability at the concentrations
used (data not shown).
Flouresence Staining
For flow-cytometric analysis, cells were fixed and permeabilized in cytofix/per-
meablization solution (BD PharMingen) and stained with PE or APC anti-Foxp3
(eBioscience).
Construction of Reporter Plasmids and Luciferase Assay
A 1019 bp fragment of Foxp3 promoter was amplified from genomic DNA by
PCR and cloned into pGL4.15 vector (Promega) between Xho I and Hind III
sites. Mlu I and Acl I sites were introduced into pGL4-Foxp3 promoter vector
by Site-Directed Mutagenesis PCR using QiuckChange XL Kit from Strate-
gene. A 182 bp fragment of Foxp3 enhancer were amplified by PCR and
cloned into HindIII and Mlu I sites, and a 973 bp fragment of silencer were
amplified by PCR and cloned into Mlu I and Acl I sites. AP-1, Stat3, and
RAR binding sites were deleted by Site-Directed Mutagenesis PCR. All the
plasmids were sequenced to verify the insertions and deletions. Luciferase
assay were performed in LBRM and EL4 cells. We transfected 4 3 106 cells
by Amaxa nuclear transfection kit (program C-009) using 8 mg firefly luciferase
reporter plasmid and 30 ng phRL-SV40 (for LBRM) or 50 ng phRL-TK (for EL4)
Renilla luciferase plasmid as an internal control. Four hours after transfection,
cells were split and stimulated with plate bound anti-CD3 (7 mg/ml), soluble
anti-CD28 (2 mg/ml), rTGF-b (2 ng/ml), and all-trans retinoic acid as indicated.
Twenty-four hours later, luciferase activity was analyzed by Dual-Glo Lucif-
erase Reporter Assay System (Promega). Data were shown as the absolute
ratio of firefly luciferase activity to Renilla luciferase activity from the samewell.
Chromatin Immunoprecipitation Assay
Mouse CD4+ T cells were stimulated with plate-bound anti-CD3 (7 mg/ml),
soluble anti-CD28 (2 mg/ml) with rTGF-b (5 ng/ml), all-trans retinoic acid
(500 nM), or both. Formaldehyde (1% final concentration) was then added to
crosslink proteins and DNA. Cells were then washed and lysed in SDS lysis
buffer containing PMSF and proteinase inhibitor cocktail (active motif). Nuclei
were sonicated (Branson Sonifier, 11% amplitude) for 10 s 6 pulses to shear
DNA to 200–1500 bp. Sheared chromatins were ten times diluted and
Immunity
Regulation of Foxp3 via Control of Smad3 Bindingprecleaned with Salmon SpermDNA/protein A agarose. A proportion (2.5%) of
the diluted chromatins was kept as ‘‘input.’’ The rest of the chromatins were
incubated with 5 mg antibody or isotype IgG overnight followed by additional
incubation with Salmon Sperm DNA/protein A agarose for 1 hr and then
washed five times. The bead-bound protein-DNA complexes were eluted in
1%SDS and 0.1MNaHCO3 and crosslinks were reversed at 65C and treated
with proteinase K at 55C. Precipitated DNA was subjected to real-time PCR
using power SYBR green PCR kit (Applied Biosystem). Following primer pairs
were used: promoter region: forward: 50- gggcactcagcacaaacatgatg-03,
reverse: 50-gaggcttccttctgctccaaac-03, enhancer I region: forward: 50-caggct-
gacctcaaactcacaaag-03, reverse: 50-catacccacacttttgacctctgc-03; forward: 50-
gcttctgtgtatggttttgtgt-03, reverse: 50-atcatcacagtacatacgagga-03. Values were
normalized to corresponding input control.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
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